

20s Proteasome - Pipeline Review, H2 2020

<https://marketpublishers.com/r/28B3115B6F8EN.html>

Date: November 2020

Pages: 78

Price: US\$ 3,500.00 (Single User License)

ID: 28B3115B6F8EN

Abstracts

20s Proteasome - Pipeline Review, H2 2020

SUMMARY

According to the recently published report '20s Proteasome - Pipeline Review, H2 2020'; 20s Proteasome pipeline Target constitutes close to 9 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

20s Proteasome - 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex. The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides.

The report '20s Proteasome - Pipeline Review, H2 2020' outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1, 1 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease and Metabolic

Disorders which include indications Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Amyloidosis, Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme (GBM), Gliosarcoma, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Leukemia, Lung Transplant Rejection, Malignant Glioma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peripheral T-Cell Lymphomas (PTCL), Renal Cell Carcinoma, Small-Cell Lung Cancer and Tuberculosis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for 20s Proteasome

The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects

The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 20s Proteasome targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 20s Proteasome Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

20s Proteasome - Overview

20s Proteasome - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

20s Proteasome - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

20s Proteasome - Companies Involved in Therapeutics Development

Amgen Inc

Bristol-Myers Squibb Co

Centrax International Inc

HuniLife Biotechnology Inc

Lodo Therapeutics Corp

20s Proteasome - Drug Profiles

carfilzomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CX-13608 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HuL-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

marizomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oprozomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RTSV-5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit 20S Proteasome for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit 20s Proteasome for Tuberculosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TIR-199 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

20s Proteasome - Dormant Products

20s Proteasome - Product Development Milestones

Featured News & Press Releases

Nov 12, 2020: CHMP adopts a positive opinion recommending a change to the terms of the marketing authorisation for Kyprolis

Aug 20, 2020: FDA approves new KYPROLIS (carfilzomib) combination regimen with DARZALEX (daratumumab) and Dexamethasone in both once- and twice-weekly dosing regimens

May 14, 2020: Oncolytics Biotech announces publication of abstract on Kyprolis at the 2020 American Society of Clinical Oncology Virtual Annual Meeting

May 13, 2020: Amgen presents update on KYPROLIS at ASCO 2020

May 05, 2020: KYPROLIS (carfilzomib) patents upheld against generic manufacturer

Dec 11, 2019: Amgen reports positive data in multiple myeloma study

Dec 02, 2019: Amgen announces data to be presented on KYPROLIS (carfilzomib) at ASH 2019

Sep 13, 2019: Amgen announces phase 3 CANDOR study combining KYPROLIS (carfilzomib) and DARZALEX (daratumumab) meets primary endpoint of progression-free survival

Sep 12, 2019: Amgen highlights new data From KYPROLIS (carfilzomib) and Oncology Pipeline At IMW 2019

Aug 19, 2019: Carfilzomib (Kyprolis): reminder of risk of potentially fatal cardiac events

Jun 19, 2019: Early Indications of potential Heart Conditions Using Carfilzomib in Multiple Myeloma

Jun 13, 2019: Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

Apr 25, 2019: Amgen agree to pay a total of nearly \$24.75 million to resolve allegations that it paid kickbacks through copay assistance foundations

Mar 19, 2019: ONO submits supplemental application of Kyprolis for intravenous injection, a proteasome inhibitor, for additional dosage and administration for the treatment of relapsed or refractory multiple myeloma in Japan

Nov 01, 2018: Amgen to present new data on Carfilzomib at ASH 2018

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Amgen Inc, H2 2020
Pipeline by Bristol-Myers Squibb Co, H2 2020
Pipeline by Centrax International Inc, H2 2020
Pipeline by HuniLife Biotechnology Inc, H2 2020
Pipeline by Lodo Therapeutics Corp, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

I would like to order

Product name: 20s Proteasome - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/28B3115B6F8EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/28B3115B6F8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970